In a filing, Medtronic Plc revealed its Officer Salmon Sean acquired Company’s shares for reported $1.6 million on Jun 06 ’25. In the deal valued at $86.81 per share,18,378 shares were bought.
Then, Wall Brett A. sold 12,437 shares, generating $1,119,330 in total proceeds. Upon selling the shares at $90.00, the EVP & Pres Neuroscience now owns 40,979 shares.
Before that, Wall Brett A. bought 12,437 shares. Medtronic Plc shares valued at $1,119,330 were divested by the Officer at a price of $90.00 per share.
Wolfe Research upgraded its Medtronic Plc [MDT] rating to a Peer perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Citigroup also remained covering MDT and has increased its forecast on March 04, 2025 with a “Buy” recommendation from previously “Neutral” rating. RBC Capital Mkts revised its rating on October 10, 2024. It rated MDT as “an Outperform” which previously was an “a Sector perform”.
Price Performance Review of MDT
On Tuesday, Medtronic Plc [NYSE:MDT] saw its stock jump 1.81% to $88.75. Over the last five days, the stock has gained 3.10%. Medtronic Plc shares have risen nearly 11.87% since the year began. Nevertheless, the stocks have risen 11.10% over the past one year. While a 52-week high of $96.25 was reached on 03/10/25, a 52-week low of $75.96 was recorded on 04/09/25.
Levels Of Support And Resistance For MDT Stock
The 24-hour chart illustrates a support level at 87.39, which if violated will result in even more drops to 86.03. On the upside, there is a resistance level at 89.43. A further resistance level may holdings at 90.11.
How much short interest is there in Medtronic Plc?
A steep rise in short interest was recorded in Medtronic Plc stocks on 2025-06-13, dropping by -5.16 million shares to a total of 8.47 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 13.63 million shares. There was a decline of -60.87%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 21, 2024 when Oppenheimer resumed its ‘”a Perform”‘ rating for the stock and retained the price target to $94.
